Summary of HB 712 - Relating to Health
Bill Number: HB 712
Title: Relating to Health
Status: Act 143, effective May 30, 2025
Introduced: January 17, 2025
Classification: Bill
Subject Areas: 340B Drug Pricing Program, Affordable Health Care, Covered Entities, Discriminatory Practices, Pharmacies, Prescription Drugs, Reports
Purpose and Intent
The primary aim of HB 712 is to enhance the effectiveness and accessibility of the 340B Drug Pricing Program, which allows certain healthcare providers, known as covered entities, to purchase prescription drugs at reduced prices. This legislation seeks to address discriminatory practices that may hinder the participation of eligible entities in the program, thereby promoting affordable healthcare options for underserved populations.
Key Provisions
340B Program Enhancements: The bill mandates improvements to the administration of the 340B Drug Pricing Program, ensuring that covered entities can fully benefit from the program's intended cost savings on prescription drugs.
Reporting Requirements: Covered entities will be required to submit regular reports detailing their participation in the 340B program, including the number of prescriptions filled and the financial impact of the program on their operations.
Anti-Discrimination Measures: The bill includes provisions to prevent discriminatory practices by pharmacies and other entities that may limit access to 340B pricing for eligible patients.
Oversight and Compliance: Establishes a framework for monitoring compliance with the 340B program requirements, ensuring that covered entities adhere to the regulations set forth in the legislation.
Affected Parties
Covered Entities: Hospitals, clinics, and other healthcare providers that qualify under the 340B program will be directly impacted, as the bill aims to enhance their ability to provide affordable medications to patients.
Pharmacies: Pharmacies that participate in the 340B program will need to adjust their practices to comply with the new reporting and anti-discrimination requirements.
Patients: Underserved populations who rely on covered entities for affordable healthcare will benefit from improved access to prescription drugs.
Procedural Timeline
- Introduced: January 17, 2025
- Passed Final Reading in House: April 30, 2025
- Passed Final Reading in Senate: April 30, 2025
- Transmitted to Governor: May 1, 2025
- Signed into Law: May 30, 2025 (Act 143)
The legislative process involved multiple readings, committee reviews, and amendments, culminating in a unanimous passage in both chambers, indicating strong bipartisan support for the bill.
Conclusion
HB 712 represents a significant step towards improving the accessibility and affordability of prescription drugs for vulnerable populations through the 340B Drug Pricing Program. By addressing discriminatory practices and enhancing reporting requirements, the bill aims to ensure that covered entities can effectively serve their communities.
